Expanded laboratories to match your growing needs in vaccine development and antibody reagents

Continued growth in the development of large molecule therapeutics has constrained resources for in vivo studies and in vitro sample analysis. In addition, the COVID-19 pandemic has brought renewed urgency to vaccine research and development, emphasizing a need to protect the world against existing, re-emerging and emerging pathogens and accelerate vaccine technology innovations. With the global vaccines market projected to double from 2021 to 2028,1 pressure will increase on services supporting nonclinical development: the COVID-19 vaccine development tools market is predicted to grow annually by nearly 9% over the next six years.2 The desire for a 'one-stop' service for in vivo testing and in vitro analysis of the resulting samples is now more apparent than ever.